Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer

Recruiting in Palo Alto (17 mi)

+17 other locations

Overseen by Zev A. Wainberg, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Translational Oncology Research International

No Placebo Group

Prior Safety Data

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with previously treated unresectable or metastatic esophageal cancer or stomach cancer.

Research Team

Zev A. Wainberg, MD

Principal Investigator

Jonsson Comprehensive Cancer Center

Eligibility Criteria

Inclusion Criteria

Diagnosis of adenocarcinoma of the upper gastrointestinal tract

Metastatic or unresectable disease

Received 1-2 prior chemotherapy or biological therapy regimens for unresectable or metastatic disease

Treatment Details

Interventions

• Everolimus (mTOR inhibitor)

Participant Groups

Group I: Everolimus Experimental Treatment 2 Interventions

Patients receive oral everolimus once daily on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity

Who Is Running the Clinical Trial?

Translational Oncology Research International

Lead Sponsor

Trials

11

Recruited

420+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School

University of California, Los Angeles

Collaborator

Trials

1,594

Recruited

10,430,000+

Dr. Thomas Rando

University of California, Los Angeles

Chief Medical Officer since 2023

MD from UCLA

Amir Naiberg

University of California, Los Angeles

Chief Executive Officer since 2024

JD from UCLA